New cell therapy aims to fight hard-to-treat lymphoma
NCT ID NCT06561425
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to standard therapy. The treatment is made at the hospital using the patient's own immune cells. The study has two phases: first, finding the safest and most effective dose, then testing that dose in a larger group. About 130 participants will take part to see if the therapy can shrink tumors and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Academisch Medisch Centrum
Amsterdam, 1105 AZ, Netherlands
-
Antwerp University Hospital
Edegem, 2650, Belgium
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU De Liège
Liège, 4000, Belgium
-
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, 1200, Belgium
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Rotterdam, 3015 GD, Netherlands
-
Leiden University Medical Center
Leiden, 2333 ZA, Netherlands
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
UZ Leuven
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.